Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line
Molecular Biology Reports · 2024-12 · 51 (1)
DOI: 10.1007/s11033-024-09422-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, online erschienen am 05.04.2024. Verfasst von Hatice Şiyzen Çoban und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zeynep Kamil Women and Children Diseases Traning and Research Hospital, İstanbul, Turkey. Hauptthemen laut MEDLINE: Thioctic Acid, Ovarian Neoplasms, Antineoplastic Agents, Adenocarcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Pamukkale University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
BACKGROUND: Ovarian cancer is the leading cause of gynecological cancer deaths. One of the major challenges in treating ovarian cancer with chemotherapy is managing the resistance developed by cancer cells to drugs, while also minimizing the side effects caused by these agents In the present study, we aimed to examine the effects of a combination of alpha lipoic acid (ALA), with cisplatin and paclitaxel in ovarian cancer(OVCAR-3). METHODS: The cytotoxic effects of ALA, cisplatin and paclitaxel on OVCAR-3 cells were determined. Four groups were formed: Control, ALA, Cisplatin + Paclitaxel, ALA + Cisplatin + Paclitaxel. The effects of single and combined therapy on cell migration, invasion and colony formation were analyzed. Changes in the expression of genes related to apoptosis, cell adhesion and cell cycle were analyzed with Real-time polymerase chain reaction(RT-PCR). The oxidative stress index and The Annexin V test were performed. RESULTS: The reduction in rapamycin-insensitive companion of mTOR(RICTOR) expression in the ALA + Cisplatin + Paclitaxel group was found statistically significant(p < 0.05). The decrease in MMP-9 and - 11 expressions the ALA + Cisplatin + Paclitaxel group was statistically significant(p < 0.05). The lowest values for mitogen-activated protein kinase(MAPK) proteins were found in the ALA + Cisplatin + Paclitaxel group. No colony formation was observed in the Cisplatin + Paclitaxel and ALA + Cisplatin + Paclitaxel groups. The lowest wound healing at 24 h was seen in the ALA + Cisplatin + Paclitaxel group. CONCLUSIONS: This study is the first one to investigate the combined treatment of ALA, Cisplatin, Paclitaxel on OVCAR-3. While ALA alone was not effective, combined therapy with ALA, has been found to reduce cell invasion, especially wound healing in the first 24 h, along with tumor cell adhesion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zeynep Kamil Women and Children Diseases Traning and Research Hospital, İstanbul, Turkey.
- Department of Histology and Embryology, Faculty of Medicine, Pamukkale University, Pamukkale, Denizli, Turkey. ncil@pau.edu.tr.
- Department of Histology and Embryology, Faculty of Medicine, Pamukkale University, Pamukkale, Denizli, Turkey.
ORCID-Profile: Hatice Şiyzen Çoban, Nazlı Çil, Elif Önder, Gülçin Abban Mete
Förderung
- Pamukkale University Scientific Research Projects Coordination Unit
Zitieren
APA
Çoban, H. Ş., Çil, N., Önder, E., & Abban Mete, G. (2024). Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-024-09422-8
Vancouver
Çoban HŞ, Çil N, Önder E, Abban Mete G. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line. Molecular Biology Reports. 2024;51(1). doi:10.1007/s11033-024-09422-8
BibTeX
@article{oban2024,
author = {Çoban, Hatice Şiyzen and Çil, Nazlı and Önder, Elif and Abban Mete, Gülçin},
title = {Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line},
journal = {Molecular Biology Reports},
year = {2024},
volume = {51},
number = {1},
doi = {10.1007/s11033-024-09422-8}
}
EUVIMED